STOCK TITAN

Fate Therapeutics (FATE) Financials

FATE NASDAQ
Trailing 12 months to September 30, 2026
Revenue $4.8M -33.4% YoY
Net Income -$124.4M n/m YoY
EPS (Diluted) -$1.03 n/m YoY
Free Cash Flow -$106.8M n/m YoY
Market Cap $155.7M as of Nov 13, 2026
Price / Sales 32.8x on $4.8M revenue, trailing 12 months to September 30, 2026
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 1.2x on $133.0M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the FATE SEC filings page.

Fate Therapeutics, Inc. (FATE) reported $4.8M in revenue over the twelve months to Sep 30, 2026, down 33.4% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI FATE FY2025

Fate remains development-stage: research spending vastly exceeds revenue, while cost reductions only partially narrow cash outflows.

From FY2024 to FY2025, revenue fell 51.2% while R&D fell only 20.1%; investment remained disproportionately large relative to the commercial inflow. The company is shrinking its spending base, but not yet converting that restraint into a self-funding operating model.

Operating cash outflow narrowed from $122.9M in FY2024 to $106.1M in FY2025. Because revenue simultaneously fell 51.2%, the improvement reflects spending restraint rather than commercial expansion.

The reported liquidity measure was 23.2 months of the latest annual operating outflow, while the current ratio was 5.8x; short-term obligations were therefore modest relative to current resources. Total assets fell 27.6% and equity fell 35.0% in FY2025, while liabilities declined only 8.4%, shifting the shrinking balance sheet toward greater creditor participation.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Cash Runway Dilution R&DIntensity Revenue Progress BurnTrend BalanceSheet 56 / 100
Financial Health Score 56/100
Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Fate Therapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway
51

Fate Therapeutics, Inc. held $205.1M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $106.1M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Fate Therapeutics, Inc. scores 51/100 among other emerging companies.

Dilution
61

Dilution ranks emerging companies on the yearly rate at which their shares outstanding grew across the last three fiscal years (the last two where the earliest reports none), a slower rise ranking higher because each round of funding spreads the same business across more owners. Fate Therapeutics, Inc. scores 61/100 on it among other emerging companies.

R&D Intensity
89

Fate Therapeutics, Inc. spent $107.8M on research and development in fiscal year 2025, which was 69.9% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Fate Therapeutics, Inc. scores 89/100 among other emerging companies.

Revenue Progress
1

Revenue Progress ranks emerging companies on the yearly rate at which their revenue compounded across the last three fiscal years (the last two where the earliest reports none), counted in the currency each company reports in. Fate Therapeutics, Inc. scores 1/100 on it among other emerging companies.

Burn Trend
59

Burn Trend ranks emerging companies on how far their operating cash flow moved between the newest fiscal year and the one two years earlier, measured against the cash the earlier year used, and a move toward generating cash ranks higher. Fate Therapeutics, Inc. scores 59/100 on it among other emerging companies.

Balance Sheet
73

Fate Therapeutics, Inc.'s cash, cash equivalents and investments came to $205.1M at the end of fiscal year 2025, against $111.8M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Fate Therapeutics, Inc. scores 73/100 among other emerging companies.

Altman Z-Score Distress
-6.76

Fate Therapeutics, Inc. scores -6.76, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $1.5B against total assets of $318.9M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
1/7

Fate Therapeutics, Inc. passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), the one computable operating efficiency signal (asset turnover improving) does not pass.

Earnings Quality No Cash Backing
N/A

Fate Therapeutics, Inc. reported a net loss of $136.3M while operations used $106.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$0
YoY-100.0%
QoQ-100.0%

Fate Therapeutics, Inc. generated $0 in revenue in Q3 2026. This represents a decrease of 100.0% from the same quarter a year earlier. Against the prior quarter it is down 100.0%.

EBITDA
-$29.6M
YoYn/m
QoQn/m
5Y CAGRn/m

Fate Therapeutics, Inc.'s EBITDA was -$29.6M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$30.7M
YoYn/m
QoQn/m
5Y CAGRn/m
10Y CAGRn/m

Fate Therapeutics, Inc. reported a net loss of $30.7M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.25
YoYn/m
QoQn/m
5Y CAGRn/m
10Y CAGRn/m

Fate Therapeutics, Inc. earned -$0.25 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Free Cash Flow
-$27.8M
YoYn/m
QoQn/m
5Y CAGRn/m
10Y CAGRn/m

Fate Therapeutics, Inc. recorded an outflow of $27.8M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt
$43.9M
YoY+8.2%
QoQ+35.5%
5Y CAGR-19.4%
10Y CAGR+1.7%

Fate Therapeutics, Inc. held $43.9M in cash as of Q3 2026; no long-term debt figure is on record for that period.

Shares Outstanding
122M
YoY+5.4%
QoQ+1.5%
5Y CAGR+4.9%
10Y CAGR+13.5%

Fate Therapeutics, Inc. had 122M shares outstanding in Q3 2026. This represents an increase of 5.4% from the same quarter a year earlier. Against the prior quarter it is up 1.5%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Return on Equity
-23.1%
YoY-9.3pp
QoQ-3.4pp
5Y change-17.1pp
10Y change+11.4pp

Fate Therapeutics, Inc.'s quarterly ROE was -23.1% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 9.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 3.4 percentage points.

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not reported for Q3 2026.

Net Margin

Not reported for Q3 2026.

Capital Allocation

R&D Spending
$24.2M
YoY-6.3%
QoQ-0.7%
5Y CAGR-14.5%

Fate Therapeutics, Inc. invested $24.2M in research and development in Q3 2026. This represents a decrease of 6.3% from the same quarter a year earlier. Against the prior quarter it is down 0.7%.

Capital Expenditures
$0
YoY-100.0%
QoQ-100.0%

Fate Therapeutics, Inc. reported no capital expenditure in Q3 2026. This represents a decrease of 100.0% from the same quarter a year earlier. Against the prior quarter it is down 100.0%.

Share Buybacks

Not reported for Q3 2026.

FATE Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

FATE quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$0-100.0%$2.1M+9.2%$1.3M-20.3%$1.4M-26.4%$1.7M-43.4%$1.9M-71.8%$1.6M-15.4%$1.9M+11.0%
R&D Expenses$24.2M-6.3%$24.4M-11.1%$24.7M-15.2%$25.4M-24.4%$25.8M-25.4%$27.4M-20.7%$29.1M-9.3%$33.6M+5.6%
SG&A Expenses$8.0M-24.5%$8.8M-22.9%$9.6M-30.3%$10.7M-30.1%$10.6M-48.9%$11.4M-33.7%$13.8M-34.0%$15.3M-14.9%
Operating Income-$32.2Mn/m-$31.1Mn/m-$33.0Mn/m-$34.7Mn/m-$34.7Mn/m-$37.0Mn/m-$41.3Mn/m-$61.7Mn/m
EBITDA-$29.6Mn/m-$28.4Mn/m-$30.1Mn/m-$31.7Mn/m-$31.5Mn/m-$33.7Mn/m-$37.9Mn/m-$56.9Mn/m
Net Income-$30.7Mn/m-$30.2Mn/m-$31.2Mn/m-$32.4Mn/m-$32.3Mn/m-$34.1Mn/m-$37.6Mn/m-$52.2Mn/m
EPS (Basic)-$0.25n/m-$0.25n/m-$0.26n/m-$0.27n/m-$0.27n/m-$0.29n/m-$0.32n/m-$0.45n/m
EPS (Diluted)-$0.25n/m-$0.25n/m-$0.26n/m-$0.27n/m-$0.27n/m-$0.29n/m-$0.32n/m-$0.45n/m
Diluted Shares (Avg)124M+3.9%120M+1.6%120M+1.4%N/A119M+1.0%119M+0.9%118M+17.1%N/A

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense, Income Tax.

FATE Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

FATE quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$238.3M-30.7%$260.1M-30.0%$284.9M-28.5%$318.9M-27.6%$343.7M-30.6%$371.6M-29.7%$398.7M-30.0%$440.7M-12.9%
Current Assets$144.3M-34.8%$158.0M-31.4%$179.5M-27.7%$208.7M-28.5%$221.3M-28.7%$230.4M-27.9%$248.2M-37.1%$291.9M-12.0%
Cash & Equivalents$43.9M+8.2%$32.4M-21.4%$39.6M-11.9%$46.6M+29.3%$40.6M+7.2%$41.2M+11.7%$44.9M-63.0%$36.1M-13.9%
Short-Term Investments$95.2M-45.5%$121.3M-33.2%$135.3M-30.8%$157.0M-35.4%$174.8M-32.5%$181.6M-32.2%$195.5Mn/m$243.0M-11.1%
Accounts Receivable$479K-29.8%$703K-49.6%$704K-70.7%$916K-74.1%$682K-83.5%$1.4M+33.1%$2.4M+180.4%$3.5M+93.8%
Long-Term Investments$0-100.0%$0-100.0%$0-100.0%$1.5M-94.7%$10.3M-69.3%$26.1M-44.7%$32.3M+325.1%$27.7M+2722.1%
Total Liabilities$105.2M-4.0%$106.7M-3.3%$105.2M-4.6%$111.8M-8.4%$109.6M-17.4%$110.3M-16.4%$110.3M-23.3%$122.0M-11.5%
Current Liabilities$32.7M+16.3%$32.6M+13.7%$30.7M+9.0%$36.1M-6.4%$28.1M-24.9%$28.7M-17.6%$28.2M-37.9%$38.5M-1.5%
Non-Current Liabilities$72.6M-11.0%$74.1M-9.2%$74.5M-9.2%$75.7M-9.3%$81.5M-14.4%$81.6M-15.9%$82.1M-16.6%$83.4M-15.5%
Total Equity$133.0M-43.2%$153.4M-41.3%$179.7M-37.7%$207.2M-35.0%$234.1M-35.4%$261.4M-34.2%$288.4M-32.3%$318.7M-13.5%
Retained Earnings-$1.6Bn/m-$1.6Bn/m-$1.6Bn/m-$1.5Bn/m-$1.5Bn/m-$1.5Bn/m-$1.4Bn/m-$1.4Bn/m

Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.

FATE Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

FATE quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$27.8Mn/m-$23.4Mn/m-$30.8Mn/m-$23.3Mn/m-$24.4Mn/m-$24.6Mn/m-$33.8Mn/m-$27.8Mn/m
Depreciation & Amortization$2.7M-17.0%$2.8M-15.2%$2.9M-12.5%$3.1M-36.4%$3.2M-30.0%$3.3M-30.6%$3.3M-30.9%$4.8M-1.5%
Stock-Based Compensation$2.7M-44.5%$3.5M-50.8%$3.9M-46.8%N/A$4.9M-58.7%$7.2M-25.7%$7.4M-32.8%N/A
Capital Expenditures$0-100.0%$80K-94.1%$239K-80.0%$1.2M+1116.3%$2.2M+345.1%$1.4M+2570.6%$1.2M+1290.7%$98K-45.9%
Free Cash Flow-$27.8Mn/m-$23.5Mn/m-$31.1Mn/m-$24.5Mn/m-$26.6Mn/m-$25.9Mn/m-$35.0Mn/m-$27.9Mn/m
Investing Cash Flow$26.8M+26.2%$14.6M-25.7%$23.6M-44.7%$27.6M+21.1%$21.3M-16.5%$19.6Mn/m$42.7M+146.5%$22.8M-49.7%
Financing Cash Flow$7.6M+207.9%N/AN/A$1.7M-46.0%$2.5Mn/m$1.3M+4.0%$0-100.0%$3.1Mn/m

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

FATE Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

FATE quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating MarginN/A-1495.4%-2540.4%-2536.2%-1995.1%-1938.5%-2534.1%-3319.8%
Net MarginN/A-1448.6%-2402.8%-2364.8%-1852.4%-1786.6%-2309.5%-2803.9%
Return on Equity-23.1%-9.3pp-19.7%-6.6pp-17.4%-4.3pp-15.6%+0.7pp-13.8%-0.6pp-13.0%-3.4pp-13.0%-1.8pp-16.4%-4.4pp
Return on Assets-12.9%-3.5pp-11.6%-2.4pp-11.0%-1.5pp-10.2%+1.7pp-9.4%+0.3pp-9.2%-1.9pp-9.4%-1.0pp-11.8%-3.1pp
Current Ratio4.41-3.5x4.85-3.2x5.85-3.0x5.79-1.8x7.87-0.4x8.04-1.1x8.81+0.1x7.58-0.9x
Liabilities-to-Equity0.79+0.3x0.70+0.3x0.59+0.2x0.54+0.2x0.47+0.1x0.42+0.1x0.380.0x0.380.0x
Asset Turnover0.000.0x0.010.0x0.000.0x0.000.0x0.010.0x0.010.0x0.000.0x0.000.0x
FCF MarginN/A-1127.8%-2391.1%-1790.1%-1526.5%-1360.7%-2148.9%-1499.8%

Not reported in any period shown, so not listed: Gross Margin, Debt-to-Equity.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Fate Therapeutics, Inc. FATE FY2025 $6.6M -$136.3M N/A $155.7M 56/100
Zentalis Pharmaceuticals, Inc. ZNTL FY2025 $0 -$137.1M N/A $167.1M —
ALX Oncology Holdings Inc. ALXO FY2025 N/A -$101.7M N/A $143.8M —
Sutro Biopharma, Inc. STRO FY2025 $102.5M -$191.1M N/A $163.0M 42/100
enGene Therapeutics Inc. ENGN FY2025 N/A -$117.3M N/A $161.5M —
NeOnc Technologies Holdings, Inc. NTHI FY2025 $40K N/A N/A $141.7M —

Frequently Asked Questions

Fate Therapeutics, Inc. (FATE) reported $6.6M in total revenue for fiscal year 2025. This represents a -51.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Fate Therapeutics, Inc. (FATE) revenue declined by 51.2% year-over-year, from $13.6M to $6.6M in fiscal year 2025.

No, Fate Therapeutics, Inc. (FATE) reported a net loss of $124.4M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $136.3M.

Fate Therapeutics, Inc. (FATE) reported diluted earnings per share of -$1.15 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Fate Therapeutics, Inc. (FATE) had EBITDA of -$134.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Fate Therapeutics, Inc. (FATE) has a return on equity of -65.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Fate Therapeutics, Inc. (FATE) recorded an outflow of $112.0M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Fate Therapeutics, Inc. (FATE) recorded an outflow of $106.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Fate Therapeutics, Inc. (FATE) had $318.9M in total assets as of fiscal year 2025, including both current and long-term assets.

Fate Therapeutics, Inc. (FATE) invested $6.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Fate Therapeutics, Inc. (FATE) invested $107.8M in research and development during fiscal year 2025.

Fate Therapeutics, Inc. (FATE) had 116M shares outstanding as of fiscal year 2025.

Fate Therapeutics, Inc. (FATE) had a current ratio of 5.79 as of fiscal year 2025, which is generally considered healthy.

Fate Therapeutics, Inc. (FATE) had a liabilities-to-equity ratio of 0.54 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

Fate Therapeutics, Inc. (FATE) had a return on assets of -42.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Fate Therapeutics, Inc. (FATE) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $155.7M as of Nov 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Fate Therapeutics, Inc. (FATE) trades at 32.8x sales, its market capitalization divided by $4.8M revenue, trailing 12 months to September 30, 2026. The market capitalization is $155.7M as of Nov 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Fate Therapeutics, Inc. (FATE) held $205.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $106.1M over that year. Dividing the one by the other, the reported balance equals about 23 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Fate Therapeutics, Inc. (FATE) has an Altman Z-Score of -6.76, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Fate Therapeutics, Inc. (FATE) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Fate Therapeutics, Inc. (FATE) reported a net loss of $136.3M while operations used $106.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Fate Therapeutics, Inc. (FATE) scores 56 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top